Supported by NIH OT2OD032644 (A.Y.L, C.S.L), NIH/NIA R01AG060942 (C.S.L.), Research to Prevent Blindness (A.Y.L., C.S.L), the C. Dan and Irene Hunter Endowed Professorship (A.Y.L), the Klorfine Family Endowed Chair (C.S.L), the Latham Vision Research Innovation Award (Seattle, WA) (A.Y.L., C.S.L), the Karalis Johnson Retina Center (A.Y.L, C.S.L), and by an unrestricted grant from Research to Prevent Blindness (A.Y.L., C.S.L.). The sponsors or funding organizations had no role in the design or conduct of this research.
Disclosure: N. Gim, None; Y. Wu, None; M. Blazes, None; C.S. Lee, Boehringer Ingelheim (C); R.K. Wang, Carl Zeiss Meditec (F), Colgate Palmolive Company (F), Estee Lauder Inc. (F), Carl Zeiss Meditec (C), Cyberdontics (C), US8,750,586 (P), US8,180,134 (P), US9,282,905 (P), US9,759,544 (P), US 10,354,378 (P), and US10,529,061 (P); A.Y. Lee, Genentech/Roche (C), Johnson and Johnson (C), Boehringer Ingelheim (C), Topcon (F), Carl Zeiss Meditec (F), Optomed (S), Heidelberg (S), Microsoft (S), Amazon (S), Meta (S)